drugset
drugset / Trial / NCT06355349

To Evaluate the Safety and PK Characteristics in Healthy Volunteers

NCT06355349 ↗

Phase 1 Completed 46 enrolled JW Pharmaceutical
RandomizedSequentialOpen-labelOther

Summary

The objective is to evaluate the safety and pharmacokinetic characteristics after co-administration of JW0101 and C2101 and administration of JW0102 in healthy volunteers under fasting conditions

Timeline

Start
2023-04-28
Primary completion
2023-07-10
Completion
2023-07-17

Drugs

EvaluationDrugModalityDoseRoute
Subject C2101 Unknown — Oral
Subject JW0101 Unknown — Oral
Subject JW0102 Unknown — Oral

Indications

No indication recorded.